New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
19:25 EDTMDTMedtronic finds biventricular pacing may offer significant clinical advantage
Medtronic announced interim findings from the BLOCK HF trial, which show that biventricular pacing may offer a significant clinical advantage and improved patient outcomes over conventional right ventricular pacing among patients with left ventricular systolic dysfunction and atrioventricular block who are indicated for a pacemaker. Presented as a late-breaking clinical trial at the American Heart Association's 2012 Scientific Sessions, BLOCK HF shows a 27% relative risk reduction in the composite of death and healthcare utilization visits requiring intravenous heart failure therapy among this patient population. The CRT devices used in the BLOCK HF trial are not approved by the FDA for the patient population studied at this time.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:06 EDTMDTMedtronic completes acquisition of Covidien for $49.9B
Subscribe for More Information
07:17 EDTMDTSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
07:08 EDTMDTMedtronic pending acquisition of Covidien approved by Irish High Court
Subscribe for More Information
January 23, 2015
16:33 EDTMDTMedtronic reports 5.1% passive stake in Intersect ENT
Subscribe for More Information
15:46 EDTMDTPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTMDTMedtronic receives FDA approval for for the Medtronic Enterra II System
Subscribe for More Information
January 21, 2015
18:06 EDTMDTS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use